Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study

NCT02689440 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02689440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 19, 2016
Completion date
December 31, 2040
Enrollment
155 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase chronic myelogenous leukemia, bcr-abl1 positive, philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia